All Stories

  1. Association of SLC13A2 rs11567842 genotypes with kidney function in calcium–oxalate stone disease: a feasibility study in a Ukrainian cohort
  2. Прогностичні моделі оцінки виживаності ниркового трансплантата: огляд літератури
  3. Спонтанна субкапсулярна гематома нирки на тлі антикоагулянтної терапії: клінічний випадок феномену Page kidney з успішним консервативним веденням
  4. Lipoprotein Combine Index Is Associated with Multi-Compartment Oxidative Stress in Clinically Stable Peritoneal Dialysis Patients: A Cross-Sectional Study
  5. The peritoneum in perspective: extracellular vesicles and the future of peritoneal dialysis
  6. Serum Cytokine Levels in Patients with Elevated Oxalic and Uric Acid Levels in the Context of Chronic Kidney Disease
  7. Serum magnesium and risk of arteriovenous fistula thrombosis in hemodialysis: a retrospective cohort study
  8. Serum Magnesium and Risk of Arteriovenous Fistula Thrombosis in Hemodialysis: A Retrospective Cohort Study
  9. #177 Association of SLC13A2 genotypes with the risk of kidney function decline in patients with nephrolithiasis in Ukraine
  10. #626 Association between peritoneal uric acid clearance, inflammation, and peritoneal membrane function in normouricemic patients undergoing peritoneal dialysis
  11. Magnesium status and clinical outcomes in kidney transplant recipients: Systematic review and meta-analysis
  12. Modular Strategies for Nephron Replacement and Clinical Translation
  13. Association between triglyceride levels and peritonitis episodes in patients undergoing peritoneal dialysis: A single-center retrospective study
  14. Modular Strategies for Nephron Replacement and Clinical Translation
  15. Імунологічні детермінанти тривалого функціонування трансплантованої нирки як терапевтичні мішені
  16. Balancing Stone Prevention and Kidney Function: A Therapeutic Dilemma
  17. LOW URIC ACID CLEARANCE PREDICTS INCREASED CARDIOVASCULAR MORTALITY IN NORMOURECEMIC PERITONEAL DIALYSIS PATIENTS
  18. Retrospective analysis of statin use and arteriovenous fistula thrombosis in hemodialysis: Is there a dose-dependent effect?
  19. Неімуноопосередковані детермінанти тривалості функціонування трансплантованої нирки
  20. Association between serum total indoxyl sulfate, intraperitoneal inflammation, and peritoneal dialysis technique failure: a 3-year prospective cohort study
  21. Probiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials
  22. Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes
  23. Контраст-асоційоване гостре пошкодження нирок: клінічні рекомендації Української асоціації нефрологів і фахівців з трансплантації нирки
  24. Смертність у хворих на ХХН VГД з постковідним синдромом: багатоцентрове, проспективне, когортне дослідження
  25. Impact of dyslipidemia on oxidative stress in patients undergoing peritoneal dialysis: A cross-sectional study
  26. Pre-Infection Nutritional Status, Oxidative Stress, and One-Year-Long COVID Persistence in Patients Undergoing Hemodialysis: A Prospective Cohort Study
  27. #612 Serum citrulline level is associated with oxidative stress and chronic kidney disease progression
  28. LOW HIGH-DENSITY LIPOPROTEIN LEVEL PROMOTES INFLAMMATORY RESPONSE IN LONG COVID PATIENTS UNDERGOING HEMODIALYSIS ONE YEAR AFTER INFECTION
  29. Pre-infection Nutritional Status, Oxidative Stress, and One-Year Long COVID Persistence in Patients Undergoing Hemodialysis: A Prospective Cohort Study
  30. WCN24-1324 DYSLIPIDEMIA AND ULTRAFILTRATION CAPACITY IN PERITONEAL DIALYSIS: A CROSS-SECTIONAL ASSESSMENT
  31. Hemodialysis dose and long-term COVID-19 outcomes – a retrospective cohort study
  32. Association between serum total indoxyl sulfate, intraperitoneal inflammation, and peritoneal dialysis technique failure: a 3-year prospective cohort study
  33. Editorial: The evolution of glomerular filtration rate estimation: Embracing the new EKFC equation
  34. IL-6 and IL-17 as potential links between pre-existing hypertension and long-term COVID sequelae in patients undergoing hemodialysis: a multicenter cross-sectional study
  35. SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
  36. LOW HIGH-DENSITY LIPOPROTEIN LEVEL ASSOCIATED WITH ENHANCED INFLAMMATORY RESPONSE AND ONE-YEAR PERSISTENCE OF LONG COVID IN PATIENTS UNDERGOING HEMODIALYSIS: A CROSS-SECTIONAL COHORT STUDY
  37. Gut Microbiota’s Oxalate-Degrading Activity and Its Implications on Cardiovascular Health in Patients with Kidney Failure: A Pilot Prospective Study
  38. OXALIC ACID LEVELS IMPACT CYTOKINE PRODUCTION LEADING TO GREATER CHRONIC INFLAMMATION IN CHRONIC KIDNEY DISEASES
  39. Myeloperoxidase/paraoxonase ratio as a prognostic marker for post-COVID syndrome in patients undergoing hemodialysis: A cross-sectional cohort study
  40. Oxidative stress as the bridge between dyslipidemia and peritoneal ultrafiltration failure: A bi-center cross-sectional cohort study
  41. IL-6 and IL-17 as potential links between pre-existing hypertension and long-COVID sequelae in patients undergoing hemodialysis: A multicenter cross-sectional study
  42. Association between hypercholesterolemia and oxalate homeostasis in a rats
  43. Low high-density lipoprotein level is a risk factor for postvaccination COVID-19 in hemodialysis patients
  44. Oxalate Homeostasis in Non-Stone-Forming Chronic Kidney Disease: A Review of Key Findings and Perspectives
  45. #2518 EFFECT OF VACCINATION ON OXIDANT/ANTIOXIDANT STATUS IN HEMODIALYSIS PATIENTS WITH POST-COVID CONDITIONS
  46. #2594 ELEVATED SERUM IL-17 LEVEL IS ASSOCIATED WITH THE PERSISTENCE OF POST-COVID SYNDROME AND VACCINATION STATUS IN HEMODIALYSIS PATIENTS
  47. #2600 INCIDENCE RATE, OUTCOMES, AND RISK FACTORS ASSOCIATED WITH COVID-19 INFECTION IN FULLY MRNA-VACCINATED HEMODIALYSIS PATIENTS
  48. #3252 PRESEPSIN AS A POTENTIAL BIOMARKER FOR RENAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
  49. OXALATE-DEGRADING ACTIVITY IN FECAL MICROBIOTA IS ASSOCIATED WITH OBESITY AND CARDIOVASCULAR EVENTS IN END-STAGE KIDNEY DISEASE PATIENTS
  50. PREDICTION OF ATHEROSCLEROSIS DEVELOPMENT AND MODIFICATION OF ITS RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
  51. The Gut-Peritoneum Axis in Peritoneal Dialysis and Peritoneal Fibrosis
  52. UNCONTROLLED BLOOD PRESSURE BEFORE COVID-19 IS ASSOCIATED WITH ELEVATED SERUM IL-17 AND LONG-COVID SEQUELAE IN HEMODIALYSIS PATIENTS
  53. Pre-existing serum indoxyl sulfate and COVID-19 outcomes in patients undergoing hemodialysis: A retrospective cohort study
  54. IL-6 and IL-17 may provide a potential link between hypertension and long-COVID sequelae in hemodialysis patients: A multicenter cross-sectional study
  55. WCN23-0089 SERUM INDOXYL SULFATE IS ASSOCIATED WITH COVID-19 INFECTION AND DISEASE SEVERITY IN HEMODIALYSIS PATIENTS
  56. WCN23-0701 ELEVATED PLASMA OXALIC ACID PROMOTES CHRONIC INFLAMMATION IN STAGE 1-3 CKD PATIENTS
  57. One year of the full-scale war in Ukraine and kidney replacement therapy: Where do we stand now? A brief report of the Ukrainian Renal Disaster Relief Committee of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  58. Long-COVID sequelae are associated with oxidative stress in hemodialysis patients
  59. Pro- Pre- and Synbiotic Supplementation and Oxalate Homeostasis in 3 PM Context: Focus on Microbiota Oxalate-Degrading Activity
  60. Baseline high-density lipoprotein level is associated with COVID-19 pneumonia severity in hemodialysis patients
  61. Beneficial pleiotropic effects of atorvastatin in peritoneal dialysis patients withdrawn by author
  62. Serum indoxyl sulfate level predicts atherogenic dyslipidemia in dialysis patients
  63. Recommendations of the Ukrainian Renal Disaster Relief Committee of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists regarding medical care to kidney disease patients during the war
  64. Pilot testing for long-term impact of glycerol-induced acute kidney injury on oxalate homeostasis in rats
  65. Specialized medical care for chronic kidney disease patients during the war in Ukraine
  66. Peritoneal dialysis and peritoneal fibrosis: molecular mechanisms, risk factors and prospects for prevention
  67. Lifesaving Care for Patients with Kidney Failure during the War in Ukraine 2022
  68. MO682: Serum Total Indoxyl Sulfate is Associated with Intraperitoneal Inflammation and High Peritonitis Episodes in Peritoneal Dialysis Patients
  69. MO825: Low High-Density Lipoprotein Level Predicts Covid-19 Severity and Mortality in Haemodialysis Patients
  70. MO878: Does Haemodiafiltration Versus Haemodialysis Have Clinical Benefits for Covid-19 Severity and Mortality in Maintenance Haemodialysis Patients?
  71. Long COVID-19 laboratory findings in hemodialysis patients: Should they be considered post-COVID syndrome?
  72. War in Ukraine: the price of dialysis patients’ survival
  73. How Advanced Is Our Understanding of the Role of Intestinal Barrier Dysfunction in the Pathogenesis of Recurrent Urinary Tract Infections
  74. Synbiotic supplementation and oxalate homeostasis in rats: focus on microbiota oxalate-degrading activity
  75. POS-960 ASSOCIATION OF PARATHYROID HORMONE LEVEL WITH SEVERITY OF CORONAVIRUS-INDUCED PNEUMONIA IN HEMODIALYSIS PATIENTS
  76. Post-COVID syndrome in dialysis patients and kidney transplant recipients
  77. Oxalate Balance in Peritoneal Dialysis Patients: A Potential Role of Dialysis-related Peritonitis
  78. Plasma oxalic acid and cardiovascular risk in end-stage renal disease patients: a prospective, observational cohort pilot study
  79. State Institution ‘Institute of Nephrology of the National Academy of Medical Sciences of Ukraine’: 20 years afterward
  80. High-density lipoproteins and clinical outcomes of COVID-19 in hemodialysis patients: A multicenter, propensity-score matched case-control study
  81. Synbiotic Supplementation And Oxalate Homeostasis In Rats: Focus On Microbiota Oxalate-Degrading Activity
  82. Altered total fecal oxalate-degrading activity is associated with atherosclerosis and systemic inflammation in end-stage renal disease patients
  83. Atherogenic effect of plasma oxalic acid in end-stage renal disease patients
  84. Fabry disease: A single-center experience
  85. Ceftriaxone-induced disruption of oxalate homeostasis is associated with total fecal microbiota oxalate-degrading activity but not with the numbers of oxalate-degrading bacteria in the experimental rats
  86. History of studying the kidney pathology in the mirror of numismatics. Report 3. Development of urology
  87. Role of Impaired Oxalate Homeostasis in Cardiovascular Disease in Patients With End-Stage Renal Disease: An Opinion Article
  88. MO311THE ASSOCIATION BETWEEN NEPHROTIC-RANGE PROTEINURIA AND OXALATE METABOLISM VIOLATION IN PATIENTS WITH PRIMARY GLOMERULONEPHRITIS
  89. FC 044THE LONG-TERM EFFECTS OF ACUTE KIDNEY INJURY ON INTESTINAL OXALATE-DEGRADING BACTERIA IN RATS
  90. MO692COULD THE RESIDUAL RENAL FUNCTION REMAIN A KEY DETERMINANT OF PLASMA OXALIC ACID CONCENTRATION IN PERITONEAL DIALYSIS PATIENTS?
  91. Crosstalk between proteinuria, plasma oxalic acid and inflammation in glomerulonephritis patients: an exploratory study
  92. POS-812 PLASMA OXALIC ACID AS A SIGNIFICANT RISK FACTOR FOR CARDIOVASCULAR DISEASE IN END-STAGE RENAL DISEASE PATIENTS
  93. A potential role of fecal oxalate-degrading activity in oxalate homeostasis in end-stage renal disease patients; a descriptive pilot study
  94. Prevention, diagnosis and management of acute kidney injury: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  95. Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients
  96. Nephrology in Ukraine
  97. Фактори ризику тяжкого перебігу COVID-19 у пацієнтів, які лікуються методом гемодіалізу
  98. Hyperuricemia Predicts Residual Diuresis Decline in Peritoneal Dialysis Patients
  99. The oxidative status in patients with chronic kidney disease
  100. Prevention, diagnosis and management of influenza in CKD patients: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  101. Serum uric acid and renal survival prognosis in primary glomerulonephritis patients in a retrospective single-center cohort
  102. Management of acute kidney injury in patients with COVID-19 or CKD stage 1-4 patients with acute kidney injury in the COVID-19 pandemic: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  103. Management of chronic kidney disease patients during the COVID-19 pandemic: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  104. Management of hemodialysis facilities and services during the COVID-19 pandemic: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  105. Management of peritoneal dialysis facilities and services during the COVID-19 pandemic: Adapted clinical guidelines of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists
  106. Hyperoxaluria; a risk factor or a consequence of recurrent pyelonephritis?
  107. P1215INVERSE ASSOCIATION BETWEEN DIALYSATE OXALATE REMOVAL AND INTRAPERITONEAL INFLAMMATION IN PERITONEAL DIALYSIS PATIENTS
  108. SO011OXALATE-DEGRADING ACTIVITY IN FECAL MICROBIOTA ASSOCIATED WITH BLOOD LIPID PROFILE IN DIALYSIS PATIENTS
  109. P0176REGULATION OF OXALATE HOMEOSTASIS BY OXALATE-DEGRADING ACTIVITY IN FECAL MICROBIOTA IN DIALYSIS PATIENTS
  110. P1591SERUM PARAOXONASE 1 ARYLESTERASE ACTIVITY AS AN ANTIOXIDANT MARKER IN DIALYSIS PATIENTS
  111. P0361THE PREDICTIVE VALUE OF SERUM URIC ACID IN PRIMARY GLOMERULONEPHRITIS PATIENTS: A 5-YEARS RENAL PROGNOSIS
  112. History of studying the kidney pathology in the mirror of numismatics. Report 2. Development of nephrology
  113. History of studying the kidney pathology in the mirror of numismatics. Report 1. Antiquity and middle ages
  114. Uric acid and the risk of kidney failure in primary glomerulonephritis patients with nephrotic syndrome: preliminary results of an ongoing single-center prospective study
  115. Arylesterase activity of paraoxonase 1 and intensity of oxidative processes in the blood of dialysis patients
  116. Cytokines and SLPI profiles in children and adults with urinary tract infections
  117. Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study
  118. Activity 0f Lipoprotein-Associated Paraoxonase-1 Enzymes and Myeloperoxidase in Patients with Chronic Kidney Disease
  119. Urinary and peritoneal uric acid excretion is associated with peritoneal dialysis technique failure
  120. EFFECT OF ANTIBIOTICOTHERAPY ON THE TOTAL AMOUNT OF OXALATE-DEGREADING BACTERIA IN THE RATS INTESTINAL TRACT
  121. Association between Dyslipidemia and Peritoneal Dialysis Technique Survival
  122. CARDIAC AUTONOMIC DYSFUNCTION & PERITONEAL DIALYSIS TECHNIQUE SURVIVAL
  123. FP572EXTRACELLULAR OVERHYDRATION IN PERITONEAL DIALYSIS PATIENTS LINKED WITH INCREASED OXIDATIVE STRESS
  124. FP587HYPERURICEMIA IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN PERITONEAL DIALYSIS PATIENTS
  125. SP374OXIDATIVE STATUS IN HEMODIALYSIS PATIENTS WITH ERYTHROPOIETIN HYPORESPONSIVENESS ANEMIA
  126. FP575URIC ACID INDUCES INTRAPERITONEAL INFLAMMATION IN PERITONEAL DIALYSIS PATIENTS
  127. Dose-dependent effect of continuous erythropoietin receptor activator on cardiac autonomic nervous activity and cardiovascular events in patients treated with online hemodiafiltration
  128. The predictive value of hyperuricemia in residual diuresis decline in peritoneal dialysis patients
  129. Can hyperoxaluria cause kidney damage in women with recurrent pyelonephritis?
  130. Anemia & antihypertensive medications
  131. Overhydration, increased oxidative stress & peritoneal dialysis adequacy
  132. Oxidative stress in peritoneal dialysis patients
  133. Plant Extracts in Hyperoxaluria Treatment: A Review of Experimental and Clinical Research
  134. Serum leptin predicts peritoneal dialysis adequacy
  135. The dose of continuous erythropoietin receptor activator & oxidative stress in hemodialysis patients
  136. Вікові особливості оксидативного стресу у пацієнтів з пієлонефритом
  137. Antioxidant effects of immunomodulators in patients with recurrent pyelonephritis
  138. FP476DOES PERITONEAL DIALYSIS REALLY INTENSIFY THE CARBOHYDRATE EXCHANGE DISORDERS IN NONDIABETIC PATIENTS?
  139. SP357IMPACT OF AMLODIPINE ON IRON AND ERYTHROPOIETIN DOSES DURING ANEMIA TREATMENT OF HEMODIALYSIS PATIENTS
  140. SP506THE ASSOCIATION OF DYSLIPIDEMIA WITH INTRAPERITONEAL INFLAMMATION & PERITONEAL DIALYSIS TECHNIQUE SURVIVAL
  141. SP632AMLODIPINE USE AND INCREASED MORTALITY IN HAEMODIALYSIS PATIENTS
  142. FP008HYPEROXALURIA-ASSOCIATED ALTERATIONS OF THE INTESTINAL COLONIZATION RESISTANCE IN PATIENTS WITH RECURRENT PYELONEPHRITIS
  143. The effects of gut indigenous microbiota on intensity of oxidative stress and the cytokine immunity in women with recurrent pyelonephritis.
  144. Intestinal barrier dysfunction in hyperoxaluria women with recurrent pyelonephritis
  145. Lactobacillus probiotic decreases urinary oxalate excretion in non-stone formers women with recurrent pyelonephritis
  146. Dependence of quantitative composition of oxalate-degrading bacteria in fecal biopsy of rats on the quantity of oxalates in the diet
  147. OPTIMIZATION OF PERITONEAL DIALYSIS ІN 7 STEPS OF EDUCATIONAL WORK WITH A PATIENT
  148. PERITONEAL DIALYSIS IN TREATMENT FOR PATIENTS WITH ACUTE KIDNEY INJURY
  149. FEATURES OF THE MICROBIAL SPECTRUM UROGENITAL SYSTEM OF WOMEN WITH RECURRENT PYELONEPHRITIS
  150. PECULIARITIES OF IMMUNITY IN PATIENTS WITH DIABETES MELLITUS AND CHRONIC PYELONEPHRITIS
  151. PERITONEAL DIALYSIS TECHNIQUE SURVIVAL: A SINGLE-CENTER EXPERIENCE ANALYSIS OF THE PERITONEAL DIALYSIS TREATMENT IN A SINGLE CENTER
  152. THE STATE OF MUCOSAL IMMUNITY AND MICROBIOCENOSIS OF THE GENITOURINARY TRACT IN PATIENTS WITH CHRONIC RECURRENT PYELONEPHRITIS
  153. SYMPATHETIC HYPERACTIVITY IN CHRONIC KIDNEY DISEASE PATIENTS: FROM PATHOGENESIS TO TREATMENT
  154. EFFECTS OF LACTIC ACID BACTERIA PROBIOTIC ON URINARE OXALATE EXCRETION AND PREVENTION OF RECURRENT PYELONEPHRITIS
  155. ANTIBIOTIC- ASSOCIATED RISK THE REDUCTION OF LACTOBACILLUS SPP. IN THE INTESTINAL MICROBIOTA IN PATIENTS WITH URINARY TRACT INFECTIONS
  156. THE ASSOCIATION OF DYSLIPIDEMIA WITH INTRAPERITONEAL INFLAMMATION AND PERITONEAL DIALYSIS TECHNIQUE SURVIVAL
  157. MP013THE ANTIBIOTIC PROPHYLAXIS AFFECT ON THE COLON OXALOBACTER FORMIGENES COLONIZATION IN PATIENTS WITH RECURRENT PYELONEPHRITIS AND HYPEROXALURIA (PILOT STUDY)
  158. MP564MCP-1 INTRAPERITONEAL PRODUCTION IS ASSOCIATED WITH THE PERITONEAL DIALYSIS ADEQUACY AND TECHNIQUE SURVIVAL
  159. SP525SERUM CERULOPLASMIN LEVEL AS A PREDICTOR FOR THE PERITONEAL DIALYSIS TECHNIQUE SURVIVAL
  160. Oxidative stress and activity of angiotensin converting enzyme
  161. Intestinal colonization resistance is associated with hyperoxaluria in the patients with recurrent pyelonephritis
  162. THE ROLE OF GUT INDIGENOUS MICROBIOTA IN THE DEVELOPMENT OF OXIDATIVE STRESS IN WOMEN WITH RECURRENT PYELONEPHRITIS
  163. Intestinal Colonization Resistance and the Cytokine Response Associated with Hyperoxaluria in the Patients with Recurrent Pyelonephritis
  164. THE PRACTICAL VALUE OFOXIDATIVE STRESS MARKERS IN PATIENTS WITH PYELONEPHRITIS
  165. The gut microbiota effects on systemic immunity and its relationship with hyperoxaluria in the patients with recurrent pyelonephritis
  166. SYSTEMIC EFFECTS OF LOCAL PRODUCTIONOFPRO- AND ANTI-FIBROGENIC MEDIATORS IN PERITONEAL DIALYSIS PATIENTS
  167. COLON OXALATE-DEGRADING BACTERIA COLONIZATION IN PATIENTS WITH RECURRENT PYELONEPHRITIS AND ITS RELATIONSHIP WITH ADMINISTRATION OF ANTIBIOTICS (PILOT STUDY)
  168. HYPEROXALURIA: FORMATION MECHANISMS AND CONSEQUENCES
  169. Identification of the geometry and elastic properties of rigid inclusions in thin plate
  170. ANTIBIOTIC RESISTANCE PATTERN OF UNCOMPLICATED URINARY TRACT INFECTIONS
  171. SPECIFIC INFLAMMATORY PROTEINS IN THE BLOOD AND URINE OF PATIENTS WITH RECURRENT PYELONEPHRITIS
  172. Біомаркери прогнозування рецидивуючого перебігу пієлонефриту
  173. RATING EVALUATION OFSPECIALIZED MEDICAL CARE BYTHEPATIENTSNEPHROLOGIC PROFILE OFTHE UKRAINEPROVINSE
  174. E33 The high level of cytokines associated with hyperoxaluria in the patients with recurrent pyelonephritis
  175. E57 Hyperoxaluria in women with recurrent pyelonephritis associated with the deficit of Lactobacillus spp. in the gut and vaginal microbiota
  176. ALPHA–LIPOIC ACID ANTIOXIDANT EFFICIENCY IN TREATMENT OF PERITONEAL DIALYSIS PATIENTS
  177. PERITONEAL DIALYSISINUKRAINE: 2009–2013
  178. AUTONOMIC STATUS OF PERITONEAL DIALYSIS PATIENTS AND ITS RELATION WITH INDICATORS OFLIPID METABOLISM
  179. ANTIOXIDANT EFFECTOF NUCLEINAT SODIUM IN PATIENTS WITH CHRONIC KIDNEYDISEASE І–II STAGES: UNCOMPLICATED PYELONEPHRITIS
  180. HYPEROXALURIA AND BIOMARKERS OF MUCOSAL IMMUNITY IN PATIENTS WITH RECURRENT PYELONEPHRITIS
  181. SPECTRUM OF MICROFLORA IN URINE OF PATIENTS WITH CHRONIC RECURRENT PYELONEPHRITIS (THE TEN YEARS FOLLOWING-UP)
  182. EFFICACY OF SODIUM NUCLEINATE INCOMPLEX TREATMENT OFPATIENTS WITH RECURRENT PYELONEPHRITIS
  183. PREDICTICAL VALUE OF DETERMINING THE OXIDATIVSTRESS INDEX IN BLOOD SERUM OF PATIENTS WITH PYELONEPHRITIS
  184. EFFECTS OF IMMUNOCORRECTION ON THE STATE OF CYTOKINES AND SLPI IN PATIENTS WITH PYELONEPHRITIS
  185. Провоспалительные цитокины у больных пиелонефритом
  186. 159 The etiology of recurrent urinary tract infections in women and relation with recurrence rate
  187. Probiotics prophylaxis for recurrent urinary tract infections
  188. 185 Urine cytokines profile in women with recurrent urinary tract infections and renal scarring